Recombinant CD40L treatment protects allogeneic murine bone marrow transplant recipients from death caused by herpes simplex virus-1 infection

Blood. 1998 Dec 1;92(11):4472-8.

Abstract

Posttransplant infection associated with host immune deficiency is the major cause of nonrelapse mortality of human bone marrow transplant recipients. In a new murine model of posttransplant infection, allogeneic bone marrow transplant recipients were infected with herpes simplex virus-1 (HSV-1) via intraperitoneal inoculation 12 weeks after transplantation. Allogeneic transplant recipients with graft-versus-host disease (GVHD) had significantly increased mortality from HSV-1 encephalitis, with deficiencies of both specific anti-HSV-1 antibody and total serum IgG2a. GVHD mice displayed a Th2 cytokine profile (increased interleukin-4 [IL-4] and decreased interferon-gamma) and decreased lipopolysaccharide (LPS) responses, suggesting that both T-cell and B-cell defects contributed to the impaired production of antibody. Because passive transfer of hyperimmune serum protected mice from HSV-1 infection, we hypothesized that CD40 ligand (CD40L), which induces B-cell maturation, would protect mice from HSV-1 infection. CD40L-treated GVHD mice showed elevated IgG2a levels and increased survival compared with vehicle-treated transplant recipients.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Animals
  • Bone Marrow Transplantation / adverse effects*
  • CD40 Ligand
  • Female
  • Herpes Simplex / etiology
  • Herpes Simplex / mortality
  • Herpes Simplex / prevention & control*
  • Herpesvirus 1, Human*
  • Humans
  • Immunosuppression Therapy / adverse effects
  • Membrane Glycoproteins / therapeutic use*
  • Mice
  • Mice, Inbred CBA
  • Recombinant Proteins / therapeutic use
  • Transplantation, Homologous

Substances

  • Membrane Glycoproteins
  • Recombinant Proteins
  • CD40 Ligand